{"log_id": 3839661305468620215, "direction": 0, "words_result_num": 29, "words_result": [{"probability": {"variance": 0, "average": 0.999955, "min": 0.999955}, "location": {"width": 28, "top": 94, "height": 27, "left": 1149}, "words": "明"}, {"probability": {"variance": 8.3e-05, "average": 0.992918, "min": 0.977416}, "location": {"width": 88, "top": 158, "height": 25, "left": 184}, "words": "推荐剂量"}, {"probability": {"variance": 0.000154, "average": 0.994799, "min": 0.92688}, "location": {"width": 806, "top": 197, "height": 37, "left": 201}, "words": "()在单药治疗中(对既往接受过治疗的患者),本品的推荐剂量为350mg/m2,静脉滴注"}, {"probability": {"variance": 0.001236, "average": 0.988422, "min": 0.866855}, "location": {"width": 230, "top": 253, "height": 26, "left": 188}, "words": "3-90分钟,每3周用一次"}, {"probability": {"variance": 3.7e-05, "average": 0.996468, "min": 0.969481}, "location": {"width": 818, "top": 294, "height": 37, "left": 197}, "words": "(2)在联合治疗中(对既往未接受过治疗的患者),通过以下方案对与5-氟尿嘧啶(5-FU)"}, {"probability": {"variance": 2e-05, "average": 0.996366, "min": 0.981432}, "location": {"width": 501, "top": 345, "height": 35, "left": 186}, "words": "和亚叶酸(FA)联合应用的安全性和有效性进行了评价"}, {"probability": {"variance": 0.00548, "average": 0.978487, "min": 0.591198}, "location": {"width": 524, "top": 394, "height": 34, "left": 206}, "words": "本品加5-氟尿嘧啶(5-FU)/亚叶酸(FA)的2周治疗方案"}, {"probability": {"variance": 1.8e-05, "average": 0.99762, "min": 0.976408}, "location": {"width": 830, "top": 440, "height": 38, "left": 184}, "words": "本品的治疗推荐剂量是180mg/m2,每2周给药一次,持续静脉滴注30到90分钟,随后滴注亚"}, {"probability": {"variance": 0.001, "average": 0.983285, "min": 0.912459}, "location": {"width": 170, "top": 498, "height": 25, "left": 187}, "words": "叶酸和5-氟尿嘧啶"}, {"probability": {"variance": 0.002529, "average": 0.986445, "min": 0.667053}, "location": {"width": 831, "top": 537, "height": 37, "left": 184}, "words": "剂量调整:应在所有的不良反应恢复到NCI-CTC(国家肿瘤研究所通用毒性标准)分级标准的"}, {"probability": {"variance": 0.000233, "average": 0.995886, "min": 0.918429}, "location": {"width": 544, "top": 588, "height": 35, "left": 187}, "words": "0或1级,且与治疗相关的腹泻完全缓解之后再进行本品治疗"}, {"probability": {"variance": 1e-06, "average": 0.999182, "min": 0.995824}, "location": {"width": 828, "top": 635, "height": 34, "left": 187}, "words": "在下一次的滴注治疗开始时,要根据上一次治疗中观察到的最严重级别的不良反应,减少本"}, {"probability": {"variance": 0.007538, "average": 0.984844, "min": 0.435981}, "location": {"width": 828, "top": 682, "height": 36, "left": 187}, "words": "品和5氟尿嘧啶的剂量(如果应用此药),为有利于与治疗相关不良反应的恢复,治疗应推"}, {"probability": {"variance": 0.001057, "average": 0.991411, "min": 0.822859}, "location": {"width": 566, "top": 732, "height": 33, "left": 187}, "words": "迟1-2周。如果延迟2周后患者仍不能恢复,应该考虑停止化疗"}, {"probability": {"variance": 0.001191, "average": 0.986535, "min": 0.817759}, "location": {"width": 790, "top": 827, "height": 35, "left": 187}, "words": "当发生以下不良反应时,本品和/或5-氟尿嘧啶(如果应用此药)的剂量应减少15-20%:"}, {"probability": {"variance": 0.002488, "average": 0.984562, "min": 0.751312}, "location": {"width": 793, "top": 922, "height": 35, "left": 209}, "words": "血液学毒性〔中性粒细胞减少症4级,发热性中性粒细胞减少症(中性粒细胞减少症3-4"}, {"probability": {"variance": 0.001245, "average": 0.986623, "min": 0.831371}, "location": {"width": 537, "top": 974, "height": 31, "left": 187}, "words": "级,发热2-4级),血小板减少症及白细胞减少症(4级)"}, {"probability": {"variance": 0.000265, "average": 0.991572, "min": 0.952769}, "location": {"width": 215, "top": 1026, "height": 26, "left": 211}, "words": "非血液学毒性(3-4级)"}, {"probability": {"variance": 8e-06, "average": 0.998091, "min": 0.986803}, "location": {"width": 662, "top": 1070, "height": 33, "left": 186}, "words": "疗程本药应持续使用直到出现客观的病变进展或难以耐受的毒性时停药"}, {"probability": {"variance": 0, "average": 0.999729, "min": 0.999487}, "location": {"width": 87, "top": 1123, "height": 26, "left": 189}, "words": "特殊人群"}, {"probability": {"variance": 2.3e-05, "average": 0.996537, "min": 0.984346}, "location": {"width": 207, "top": 1173, "height": 25, "left": 207}, "words": "1)肝功能不良的患者"}, {"probability": {"variance": 0.000749, "average": 0.990731, "min": 0.865803}, "location": {"width": 828, "top": 1216, "height": 33, "left": 189}, "words": "单药治疗一一在高胆红素及凝血时间大于50%的患者中,伊立替康清除率降低,因而其血液"}, {"probability": {"variance": 1e-05, "average": 0.998008, "min": 0.985492}, "location": {"width": 444, "top": 1268, "height": 29, "left": 189}, "words": "毒性增高。在此人群中应经常进行全血细胞计数"}, {"probability": {"variance": 0.003519, "average": 0.985115, "min": 0.614968}, "location": {"width": 724, "top": 1315, "height": 33, "left": 211}, "words": "当患者的胆红素在正常值上限的1.5倍以内时(ULN),本品推荐剂量为350mg/m2"}, {"probability": {"variance": 0.001023, "average": 0.989276, "min": 0.819651}, "location": {"width": 632, "top": 1366, "height": 29, "left": 212}, "words": "当患者的胆红素在正常值上限的1.5-3倍时,本品推荐剂量为200mg/m"}, {"probability": {"variance": 1.6e-05, "average": 0.998163, "min": 0.982474}, "location": {"width": 535, "top": 1415, "height": 30, "left": 212}, "words": "当患者的胆红素超过正常值上限的3倍时,不能用本品治疗"}, {"probability": {"variance": 0.000319, "average": 0.993348, "min": 0.930704}, "location": {"width": 445, "top": 1465, "height": 28, "left": 191}, "words": "联合治疗一一目前尚无肝功能不良患者使用资料"}, {"probability": {"variance": 1e-06, "average": 0.998625, "min": 0.99599}, "location": {"width": 208, "top": 1515, "height": 28, "left": 209}, "words": "2)肾功能不良的患者"}, {"probability": {"variance": 0.000177, "average": 0.99522, "min": 0.942934}, "location": {"width": 360, "top": 1562, "height": 28, "left": 193}, "words": "目前尚未开展对肾功能不全患者的研究"}], "language": 3}